Pertuzumab, trastuzumab and docetaxel reduced the recurrence of brain metastasis from breast cancer: a case report

Senda, Noriko; Yamaguchi, Ayane; Nishimura, Hideaki; Shiozaki, Toshiki; Tsuyuki, Shigeru

doi:10.1007/s12282-015-0623-x

Cited by 9 publications

(4 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 1 Despite advances in treatment methods, such as surgery, chemotherapy, radiation therapy, and biological therapy, the percentage of death in BC patients remains high. Although targeted therapies using antibodies, such as pertuzumab and trastuzumab, have significantly improved the treatment of BC in recent years, 2 – 4 some investigations reported that 30%–70% of BC patients relapse after 5 years. 5 …”

Section: Introductionmentioning

confidence: 99%

Targeting breast cancer stem cells by dendritic cell vaccination in humanized mice with breast tumor: preliminary results

Pham

et al. 2016

OTT

View full text Add to dashboard Cite

BackgroundBreast cancer (BC) is one of the leading cancers in women. Recent progress has enabled BC to be cured with high efficiency. However, late detection or metastatic disease often renders the disease untreatable. Additionally, relapse is the main cause of death in BC patients. Breast cancer stem cells (BCSCs) are considered to cause the development of BC and are thought to be responsible for metastasis and relapse. This study aimed to target BCSCs using dendritic cells (DCs) to treat tumor-bearing humanized mice models.Materials and methodsNOD/SCID mice were used to produce the humanized mice by transplantation of human hematopoietic stem cells. Human BCSCs were injected into the mammary fat pad to produce BC humanized mice. Both hematopoietic stem cells and DCs were isolated from the human umbilical cord blood, and immature DCs were produced from cultured mononuclear cells. DCs were matured by BCSC-derived antigen incubation for 48 hours. Mature DCs were vaccinated to BC humanized mice with a dose of 106 cells/mice, and the survival percentage was monitored in both treated and untreated groups.ResultsThe results showed that DC vaccination could target BCSCs and reduce the tumor size and prolong survival.ConclusionThese results suggested that targeting BCSCs with DCs is a promising therapy for BC.

show abstract

Section: Introductionmentioning

confidence: 99%

Targeting breast cancer stem cells by dendritic cell vaccination in humanized mice with breast tumor: preliminary results

Pham

et al. 2016

OTT

View full text Add to dashboard Cite

show abstract

“…Patients like ours are usually not involved in clinical trials due to their poor performance status that is allegedly related to bad prognosis, and the optimal therapy remains an open question. Until today, only one case with brain metastases has been reported to experience complete response under second-line combination of pertuzumab-trastuzumab and docetaxel [ 20 ]. A retrospective study including patients rechallenged with trastuzumab after second-line lapatinib therapy for CNS involvement indicated a rather poor median OS of 17.3 (3.4–32.2) months [ 21 ].…”

Section: Discussionmentioning

confidence: 99%

Durable Clinical Benefit of Pertuzumab in a Young Patient with BRCA2 Mutation and HER2-Overexpressing Breast Cancer Involving the Brain

Koumarianou

Kontopoulou

Kouloulias

et al. 2016

Case Reports in Oncological Medicine

View full text Add to dashboard Cite

Patients with HER2-positive breast cancer and brain metastases have limited treatment options, and, as a result of their poor performance status and worse prognosis, they are underrepresented in clinical trials. Not surprisingly, these patients may not be fit enough to receive any active treatment and are offered supportive therapy. BRCA2 mutations are reported to be rarely associated with HER2-overexpressing advanced breast cancer and even more rarely with brain metastases at diagnosis. We report on a BRCA2-positive breast cancer patient with metastatic disease in multiple sites, including the brain, and poor performance status who exhibited an extraordinary clinical and imaging response to the novel anti-HER2 therapy pertuzumab after multiple lines of therapy including anti-HER2 targeting. To our knowledge, the clinicopathologic and therapeutic characteristics of this patient point to a unique case and an urgent need for further investigation of pertuzumab in patients with brain metastases.

show abstract

“… 76 Furthermore, in a case report, pertuzumab with trastuzumab plus docetaxel was effective in reducing the recurrence of BCBM in a patient who was heavily pretreated. 77 Based on these findings, further trials are warranted to investigate the effect of this regimen among patients with HER2-positive BCBM.…”

Section: Targeted Therapy For Her2-positive Bcbmmentioning

confidence: 99%

Management of breast cancer brain metastases: Focus on human epidermal growth factor receptor 2‐positive breast cancer

Yuan

Gao

2017

Chronic Diseases and Translational Medicine

View full text Add to dashboard Cite

After the introduction of trastuzumab, a monoclonal antibody that binds to human epidermal growth factor receptor 2 (HER2), the overall survival (OS) among patients with HER2-positive breast cancer has been substantially improved. However, among these patients, the incidence of brain metastases (BM) has been increasing and an increased proportion of them have died of intracranial progression, which makes HER2-positive breast cancer brain metastases (BCBM) a critical issue of concern. For local control of limited BM, stereotactic radiosurgery (SRS) and surgical resection are available modalities with different clinical indications. Postoperative or preoperative radiation is usually delivered in conjunction with surgical resection to boost local control. Adjuvant whole-brain radiotherapy (WBRT) should be deferred for limited BM because of its impairment of neurocognitive function while having no benefit for OS. Although WBRT is still the standard treatment for local control of diffuse BM, SRS is a promising treatment for diffuse BM as the technique continues to improve. Although large molecules have difficulty crossing the blood brain barrier, trastuzumab-containing regimens are critical for treating HER2-positive BCBM patients because they significantly prolong OS. Tyrosine kinase inhibitors are more capable of crossing into the brain and they have been shown to be beneficial for treating BM in HER2-positive patients, especially lapatinib combined with capecitabine. The antiangiogenic agent, bevacizumab, can be applied in the HER2-positive BCBM scenario as well. In this review, we also discuss several strategies for delivering drugs into the central nervous system and several microRNAs that have the potential to become biomarkers of BCBM.

show abstract

Pertuzumab, trastuzumab and docetaxel reduced the recurrence of brain metastasis from breast cancer: a case report

Cited by 9 publications

References 29 publications

Targeting breast cancer stem cells by dendritic cell vaccination in humanized mice with breast tumor: preliminary results

Targeting breast cancer stem cells by dendritic cell vaccination in humanized mice with breast tumor: preliminary results

Durable Clinical Benefit of Pertuzumab in a Young Patient with BRCA2 Mutation and HER2-Overexpressing Breast Cancer Involving the Brain

Management of breast cancer brain metastases: Focus on human epidermal growth factor receptor 2‐positive breast cancer

Contact Info

Product

Resources

About